Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease
Mariza Bortolanza, Roberta Cavalcanti-Kiwiatkoski, Fernando E. Padovan‐Neto, et al.
Neurobiology of Disease (2014) Vol. 73, pp. 377-387
Closed Access | Times Cited: 107

Showing 1-25 of 107 citing articles:

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Matthieu F. Bastide, Wassilios G. Meissner, Barbara Picconi, et al.
Progress in Neurobiology (2015) Vol. 132, pp. 96-168
Open Access | Times Cited: 430
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications
M. Angela Cenci
Frontiers in Neurology (2014) Vol. 5
Open Access | Times Cited: 204
Dopamine, Immunity, and Disease
Breana Channer, Stephanie Matt, Emily Nickoloff-Bybel, et al.
Pharmacological Reviews (2022) Vol. 75, Iss. 1, pp. 62-158
Open Access | Times Cited: 156
Doxycycline Suppresses Microglial Activation by Inhibiting the p38 MAPK and NF-kB Signaling Pathways
Flávia V. Santa-Cecília, Benjamin Socias, Mohand Ouidir Ouidja, et al.
Neurotoxicity Research (2016) Vol. 29, Iss. 4, pp. 447-459
Closed Access | Times Cited: 156
Neuroimaging of Parkinson's disease: Expanding views
Carol P. Weingarten, Mark Sundman, Patrick Hickey, et al.
Neuroscience & Biobehavioral Reviews (2015) Vol. 59, pp. 16-52
Open Access | Times Cited: 147
Significant roles of neuroinflammation in Parkinson’s disease: therapeutic targets for PD prevention
Yujeong Lee, Seulah Lee, Seung‐Cheol Chang, et al.
Archives of Pharmacal Research (2019) Vol. 42, Iss. 5, pp. 416-425
Closed Access | Times Cited: 133
Urolithins Attenuate LPS-Induced Neuroinflammation in BV2Microglia via MAPK, Akt, and NF-κB Signaling Pathways
Jialin Xu, Chunhui Yuan, Guihua Wang, et al.
Journal of Agricultural and Food Chemistry (2018) Vol. 66, Iss. 3, pp. 571-580
Closed Access | Times Cited: 123
Oxidative Stress in Parkinson’s Disease: Potential Benefits of Antioxidant Supplementation
Sandro Percário, Aline da Silva Barbosa, Everton Luiz Pompeu Varela, et al.
Oxidative Medicine and Cellular Longevity (2020) Vol. 2020, pp. 1-23
Open Access | Times Cited: 117
The Link between Gut Dysbiosis and Neuroinflammation in Parkinson’s Disease
José Fidel Baizabal‐Carvallo, Marlene Alonso-Juárez
Neuroscience (2020) Vol. 432, pp. 160-173
Closed Access | Times Cited: 98
Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l -DOPA delivery in the 6-OHDA model of Parkinson's disease
Giovanna Mulas, Elena Espa, Sandro Fenu, et al.
Experimental Neurology (2016) Vol. 286, pp. 83-92
Closed Access | Times Cited: 89
Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action
Maurício dos Santos Pereira, C.A. da-Silva, Francisco Silveira Guimarães, et al.
Neurobiology of Disease (2016) Vol. 94, pp. 179-195
Closed Access | Times Cited: 88
Epigenetic Regulation of Neuroinflammation in Parkinson’s Disease
Madiha Rasheed, Junhan Liang, Chaolei Wang, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4956-4956
Open Access | Times Cited: 59
Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease
Lori N. Eidson, George T. Kannarkat, Christopher J. Barnum, et al.
Journal of Neuroinflammation (2017) Vol. 14, Iss. 1
Open Access | Times Cited: 82
Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson’s Disease: Rationale for Clinical Trial, and Current Progress
Camille Carroll, Richard Wyse
Journal of Parkinson s Disease (2017) Vol. 7, Iss. 4, pp. 545-568
Open Access | Times Cited: 65
l‐DOPA‐induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?
Anna R. Carta, Giovanna Mulas, Mariza Bortolanza, et al.
European Journal of Neuroscience (2016) Vol. 45, Iss. 1, pp. 73-91
Open Access | Times Cited: 63
Regulation of the Neurodegenerative Process Associated to Parkinson’s Disease by CD4+ T-cells
Hugo González, Francisco Contreras, Rodrigo Pacheco
Journal of Neuroimmune Pharmacology (2015) Vol. 10, Iss. 4, pp. 561-575
Closed Access | Times Cited: 62
l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?
Elaine Aparecida Del Bel, Mariza Bortolanza, Maurício dos Santos Pereira, et al.
Synapse (2016) Vol. 70, Iss. 12, pp. 479-500
Closed Access | Times Cited: 57
Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson’s Disease and l-DOPA-Induced Dyskinesia
Nilson C. Ferreira‐Junior, Maurício dos Santos Pereira, Francisco Silveira Guimarães, et al.
Neurotoxicity Research (2019) Vol. 37, Iss. 1, pp. 12-29
Closed Access | Times Cited: 44
Angiotensin-converting enzyme inhibition prevents l-dopa-induced dyskinesia in a 6-ohda-induced mouse model of Parkinson's disease
Hye‐Yeon Park, Ga Seul Lee, Jun Go, et al.
European Journal of Pharmacology (2024) Vol. 973, pp. 176573-176573
Open Access | Times Cited: 5
Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced byl-DOPA?
Mariza Bortolanza, Fernando E. Padovan‐Neto, Roberta Cavalcanti-Kiwiatkoski, et al.
Philosophical Transactions of the Royal Society B Biological Sciences (2015) Vol. 370, Iss. 1672, pp. 20140190-20140190
Open Access | Times Cited: 48
Expression of Tgfβ1 and Inflammatory Markers in the 6-hydroxydopamine Mouse Model of Parkinson’s Disease
Stefan Haas, Xiaolai Zhou, Venissa Machado, et al.
Frontiers in Molecular Neuroscience (2016) Vol. 9
Open Access | Times Cited: 43
Rho kinase inhibitor fasudil reduces l‐DOPA‐induced dyskinesia in a rat model of Parkinson's disease
Andrea López-López, Carmen M. Labandeira, José L. Labandeira‐García, et al.
British Journal of Pharmacology (2020) Vol. 177, Iss. 24, pp. 5622-5641
Open Access | Times Cited: 35
RasGRP1 is a causal factor in the development of l -DOPA–induced dyskinesia in Parkinson’s disease
Mehdi Eshraghi, Uri Nimrod Ramírez-Jarquín, Neelam Shahani, et al.
Science Advances (2020) Vol. 6, Iss. 18
Open Access | Times Cited: 34
Cannabidiol has therapeutic potential for myofascial pain in female and male parkinsonian rats
Airam Nicole Vivanco-Estela, Maurício dos Santos Pereira, Francisco Silveira Guimarães, et al.
Neuropharmacology (2021) Vol. 196, pp. 108700-108700
Closed Access | Times Cited: 28
Neuroprotective and Anti-Inflammatory Effects of Pioglitazone on Parkinson's Disease: A Comprehensive Narrative Review of Clinical and Experimental Findings
Mohammad Yasin Zamanian, Ermias Mergia Terefe, Niloofar Taheri, et al.
CNS & Neurological Disorders - Drug Targets (2022) Vol. 22, Iss. 10, pp. 1453-1461
Closed Access | Times Cited: 20
Page 1 - Next Page

Scroll to top